Potent D-peptide inhibitors of HIV-1 entry

During HIV-1 entry, the highly conserved gp41 N-trimer pocket region becomes transiently exposed and vulnerable to inhibition. Using mirror-image phage display and structure-assisted design, we have discovered protease-resistant D-amino acid peptides (D-peptides) that bind the N-trimer pocket with high affinity and potently inhibit viral entry. We also report high-resolution crystal structures of two of these D-peptides in complex with a pocket mimic that suggest sources of their high potency. A trimeric version of one of these peptides is the most potent pocket-specific entry inhibitor yet reported by three orders of magnitude (IC50 = 250 pM). These results are the first demonstration that D-peptides can form specific and high-affinity interactions with natural protein targets and strengthen their promise as therapeutic agents. The D-peptides described here address limitations associated with current L-peptide entry inhibitors and are promising leads for the prevention and treatment of HIV/AIDS.

[1]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Bewley,et al.  Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity* , 2001, The Journal of Biological Chemistry.

[3]  Lorenz M. Mayr,et al.  Identification of d-Peptide Ligands Through Mirror-Image Phage Display , 1996, Science.

[4]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[5]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[6]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Debnath,et al.  XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. , 2002, AIDS research and human retroviruses.

[8]  M. Root,et al.  HIV-1 gp41 as a target for viral entry inhibition. , 2004, Current pharmaceutical design.

[9]  Michael S. Kay,et al.  Inhibiting HIV Fusion with a β-Peptide Foldamer , 2005 .

[10]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[12]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[13]  M. Root,et al.  Kinetic Dependence to HIV-1 Entry Inhibition* , 2006, Journal of Biological Chemistry.

[14]  M. Klein,et al.  Comparative immunological properties of enantiomeric peptides , 1996, Letters in Peptide Science.

[15]  Shibo Jiang,et al.  Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. , 2002, Angewandte Chemie.

[16]  J. Pappenheimer,et al.  Intestinal absorption and excretion of octapeptides composed of D amino acids. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Debnath,et al.  Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. , 1999, Journal of medicinal chemistry.

[18]  J. Pappenheimer,et al.  Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. , 1997, The Journal of pharmacology and experimental therapeutics.

[19]  A. Debnath,et al.  N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion , 2004, Antimicrobial Agents and Chemotherapy.

[20]  Y. G. Yu,et al.  Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.

[21]  Brett D. Welch,et al.  Steric Accessibility of the HIV-1 gp41 N-trimer Region* , 2005, Journal of Biological Chemistry.

[22]  Gennaro Ciliberto,et al.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. S. Kim,et al.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[25]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[26]  Stuart L. Schreiber,et al.  Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements , 1999, Nature Structural Biology.

[27]  Thomas Wisniewski,et al.  A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice , 2004 .

[28]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[29]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[30]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[31]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[32]  S. Kent,et al.  Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [corrected]. , 1992, Science.

[33]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[34]  Christos,et al.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Samuel K Sia,et al.  Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[37]  R. Schooley,et al.  Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion , 2006, Proceedings of the National Academy of Sciences.